The U.S. Cefpodoxime Proxetil (USP) market maintained a bullish trend in April 2026 as tightening global supply conditions and persistent freight disruptions continued to raise import costs across the pharmaceutical supply chain. The market was supported by constrained API availability from Asia, elevated logistics expenses, and strong procurement activity among U.S. pharmaceutical manufacturers. During March and April 2026, global antibiotics and API markets experienced increased volatility due to disruptions in international logistics. China and India, the leading producers of Cefpodoxime Proxetil intermediates and APIs, faced stricter inspections, high energy costs, and uneven manufacturing utilization, resulting in export delays and reduced product availability. Limited vessel availability on Asia–U.S. trade routes further affected supply inflows into the United States. Geopolitical tensions in the Middle East and disruptions around the Strait of Hormuz added further strain to global shipping operations, increasing transportation costs and causing shipment delays. At the same time, rising production and raw material costs in China and India, combined with steady demand for anti-infective drugs in North America, are expected to keep the Cefpodoxime Proxetil market firm through the second half of 2026.
